{"id":"W4236289131","doi":"10.1016/s1470-2045(21)00073-5","title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck; AstraZeneca","keywords":"Olaparib; Medicine; BRCA mutation; Internal medicine; Clinical endpoint; Ovarian cancer; Oncology; Placebo; Progression-free survival; PARP inhibitor; Randomized controlled trial; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001406134,0.001291867,0.003287844,0.0004174676,0.0003243285,0.001095934,0.0008902773,0.001550388,0.004666763],"category_scores_gemma":[0.001602662,0.0005918104,0.001825015,0.0004768669,0.0009539338,0.001303681,0.0003533113,0.002810608,0.0008294868],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005189446,"about_ca_system_score_gemma":0.0006837313,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006049051,"about_ca_topic_score_gemma":0.001442006,"domain_scores_codex":[0.9994628,0.0003021304,0.00003782546,0.00009825645,0.00003541151,0.00006371331],"domain_scores_gemma":[0.9991753,0.0003124985,0.0001654354,0.00006999048,0.00004165825,0.0002350922],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9733479,0.001581118,0.0004424025,0.0007746596,0.0009077007,0.00004113584,0.00004888525,0.0002584227,0.002182692,0.00006914138,0.0005837756,0.01976222],"study_design_scores_gemma":[0.9626267,0.03402028,0.001538276,0.00004324348,0.0003888462,0.00005025823,0.00002130711,0.0003236893,0.0002741253,0.0001240438,0.0005714992,0.00001763116],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9749531,0.01758634,0.000805132,0.0008432092,0.0005453394,0.001758812,0.001253369,0.0002145065,0.002040134],"genre_scores_gemma":[0.9871042,0.005775774,0.001193693,0.0009277305,0.0003161572,0.001158517,0.001135826,0.00003311098,0.002354912],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004666763,"threshold_uncertainty_score":0.01561195,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05218418572592092,"score_gpt":0.3670435714528127,"score_spread":0.3148593857268918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}